Osteoarthritis Pipeline Analysis: Emerging Disease-Modifying Therapies and Innovative Drug Candidates Reshaping the Future of Osteoarthritis Treatment | DelveInsight

DelveInsight's Osteoarthritis Pipeline Insight 2026 report provides comprehensive global coverage of available, marketed, and pipeline osteoarthritis therapies in various stages of clinical development. Major pharmaceutical and biotechnology companies are actively advancing innovative therapies to address the growing burden of osteoarthritis and improve long-term disease management.

Key takeaways from the Osteoarthritis Clinical Trial Landscape Report
• DelveInsight's osteoarthritis pipeline report depicts a robust therapeutic landscape with multiple companies actively working to develop innovative osteoarthritis therapies across different stages of clinical development.
• Key osteoarthritis companies such as Eli Lilly and Company, Novartis, Eupraxia Pharmaceuticals, Genascence, Sanofi, Biosplice Therapeutics, Ageless Biotech, Amzell, and PK MED are actively strengthening the osteoarthritis pipeline domain.
• Promising osteoarthritis pipeline therapies in development include Retatrutide, EP-104IAR, DFV890, GNSC-001, Lorecivivint, OA-SYS, and SAR446959.

Request a sample and discover the recent advances in osteoarthritis treatment drugs at https://www.delveinsight.com/sample-request/osteoarthritis-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

What is Osteoarthritis?
Osteoarthritis (OA) is the most common form of arthritis and a major cause of pain, stiffness, swelling, and disability in adults worldwide. Often referred to as degenerative joint disease or "wear and tear" arthritis, OA most commonly affects the knees, hips, and hands. The disease occurs when cartilage within joints gradually breaks down, leading to changes in the underlying bone and surrounding tissues. Symptoms of osteoarthritis include joint pain that worsens with activity, stiffness after periods of inactivity, swelling, joint instability, grinding sounds during movement, and reduced mobility. Osteoarthritis prevalence increases significantly with age and is more common in females than males. According to the Global Burden of Disease Study, approximately 595 million people were affected globally in 2020.

Emerging Osteoarthritis Drug Profiles

EP-104IAR: Eupraxia Pharmaceuticals
EP-104IAR is an investigational intra-articular therapy designed to provide prolonged pain relief with reduced systemic side effects. The therapy encapsulates fluticasone propionate within a patented polymer membrane technology platform, enabling slow release of corticosteroids into the knee joint for up to six months.

The therapy demonstrated clinically meaningful pain relief and favorable safety profiles in the Phase II SPRINGBOARD clinical trial. Eupraxia Pharmaceuticals has initiated Phase III development for EP-104IAR following successful interactions with the FDA regarding the 505(b)(2) approval pathway.

Retatrutide: Eli Lilly and Company
Retatrutide is a synthetic peptide therapy being developed by Eli Lilly and Company for osteoarthritis and is currently in Phase III development. The therapy acts as a GIP/GLP-1 agonist and represents a promising therapeutic approach targeting metabolic and inflammatory pathways associated with osteoarthritis progression.

Learn more about the novel and emerging osteoarthritis pipeline therapies at https://www.delveinsight.com/sample-request/osteoarthritis-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Recent Developments in the Osteoarthritis Clinical Trial Landscape
• In February 2024, Eupraxia Pharmaceuticals announced initiation of the Phase III development program for EP-104IAR following completion of its End-of-Phase II meeting with the US FDA.
• In June 2023, Eupraxia Pharmaceuticals received US Fast Track designation for EP-104IAR for the treatment of osteoarthritis.
• In October 2024, Lancet Rheumatology published positive Phase II SPRINGBOARD trial results demonstrating clinically meaningful pain relief and favorable safety outcomes with EP-104IAR in knee osteoarthritis patients.
• In July 2025, Genascence Corporation announced that the US FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to GNSC-001, a gene therapy targeting interleukin-1 (IL-1) for knee osteoarthritis treatment.
• In August 2025, AlzeCure Pharma AB announced acceptance of an abstract related to TrkA-NAM ACD137 for presentation at the NeuPSIG 2025 international pain conference.

Scope of the Osteoarthritis Pipeline Report
• Coverage: Global
• Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
• Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, IND, Phase I, Phase I/II, Phase II, Phase III
• Therapeutics Assessment By Route of Administration: Oral, Intra-articular, Intravenous, Subcutaneous, Topical
• Therapeutics Assessment By Molecule Type: Small molecules, Gene therapies, Cell therapies, Peptides, Antibodies, Proteins, Oligonucleotides, Vaccines
• Key Osteoarthritis Companies: Eli Lilly and Company, Novartis, Eupraxia Pharmaceuticals, Genascence, Sanofi, Biosplice Therapeutics, Ageless Biotech, and others.
• Key Osteoarthritis Pipeline Therapies: Retatrutide, EP-104IAR, DFV890, GNSC-001, OA-SYS, Lorecivivint, and SAR446959.

Dive deep into rich insights for new drugs for osteoarthritis treatment, visit https://www.delveinsight.com/sample-request/osteoarthritis-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Table of Contents
1. Osteoarthritis Pipeline Report Introduction
2. Osteoarthritis Pipeline Report Executive Summary
3. Osteoarthritis: Snapshot
4. Pipeline Scenario
5. Osteoarthritis: Background and Overview
6. Signs and Symptoms
7. Pathophysiology
8. Diagnosis
9. Treatment
10. Pipeline Therapeutics
11. Therapeutic Assessment
12. Late-stage Products (Phase III)
13. Mid-stage Products (Phase II)
14. Early-stage Products (Phase I/II and Phase I)
15. Preclinical-stage Products
16. Discovery-stage Products
17. Inactive Products
18. Collaborations Assessment
19. Unmet Needs
20. Market Drivers and Barriers
21. References
22. Report Methodology
23. About DelveInsight

For further information on the osteoarthritis pipeline therapeutics, reach out at https://www.delveinsight.com/sample-request/osteoarthritis-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Company Name: DelveInsight Business Research LLP
Contact Person: Kirti Sharma
Email: info@delveinsight.com
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

This release was published on openPR.